I'm interested in conversations about and I want to talk about
Know exactly what you want?
Show search

Notification

Error

zytiga

User
Posted 07 June 2017 09:59:59(UTC)

Well what about this then??

 

Doctors have developed a successful new treatment for prostate cancer that slows down the condition and helps patients avoid relapse and live longer. The fantastic new result was possible by adding a drug called abiraterone acetate (zytiga) to a standard hormone therapy.

The result is based on a clinical trial of almost 2,000 people. It shows that adding abiraterone lowered the relative risk of death by 37 percent and the 3-year survival rate to 83 percent from 76 percent based on the standard therapy alone.

The study was presented at the 2017 American Society of Clinical Oncology Annual meeting by lead author Professor Nicholas James from the Queen Elizabeth Hospital in Birmingham, UK.

“Abiraterone not only prolonged life, but also lowered the chance of relapse by 70% and reduced the chance of serious bone complications by 50%,” Professor James said in a statement. “We believe that the upfront care for patients newly diagnosed with advanced prostate cancer should change.”

The combined therapies fight the production of testosterone around the body. Testosterone stimulates the growth of prostate cancer cells so the standard treatment, known as androgen deprivation therapy (ADT), acts on the testicles and stops the production of hormones. Unfortunately, other organs, including the prostate glands, continue to produce small quantities of testosterone and this is where abiraterone comes in. The substance target the enzyme that produces testosterone and similar hormones everywhere.

The patients were followed up on average 40 months after the two types of treatment started. According to the study, over that time 262 deaths occurred in the group using standard therapy and 184 in the group using abiraterone. Of these deaths, two in the abiraterone group and one in the standard were due to the treatment.

While the therapy is promising in term of survival rate, abiraterone had more severe side effects than the standard approach. Forty-one percent of patients complained of severe side effects when taking abiraterone, compared to 29 percent from the standard group. Side effects included cardiovascular and liver problems.

Previous studies showed successful results in fighting a particularly aggressive form of prostate cancers by using a mixture of hormonal therapy and a chemotherapy drug known as docetaxel. There is a chance that some patients might benefit by including abiraterone into the mix but more studies are necessary to confirm that. The team is currently planning molecular analysis of tissue samples from patients that could benefit from the new cocktail but, for now, it’s too early to tell.

 
 
Thanked 2 times
User
Posted 08 June 2017 07:55:44(UTC)

Thanks for posting this Graham.

I missed this when it was on the news as some others may have too so to see it written down is helpful

We can't control the winds - but we can adjust our sails
User
Posted 08 June 2017 19:01:01(UTC)

I will look out for the data on this as Gary had early chemo and now on the abi/ Enzo trial ,one thing that puzzled me in the report was that they used men that had advanced disease but then went on to say that hadn't spread .i thought that by it spreading it was classed as advanced ?? .
I also believe that quite a high percentage of men have withdrawn or altered the dosage on arm j because of side effects or toxicity ,luckily Gary only suffers from fatigue at the moment and has blood tests every 4 weeks so it is monitored well .
Other men's experiences would be good to here about .
Debby

User
Posted 08 June 2017 19:14:15(UTC)

They accepted men who were either locally advanced or metastatic. Journalists probably wouldn't understand the difference between something that is locally advanced and something that has spread or metasticised

"Life can only be understood backwards; but it must be lived forwards." Soren Kierkegaard


Thanked 1 time
 
©2018 Prostate Cancer UK